Ginkgo Bioworks DNA Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$297.87M+36.9% | -$312.76M+42.8% | -$339.55M+47.9% | -$315.19M+64.9% | -$472.08M+44.7% | ||
| $56.97M-12.3% | $58.99M-6.4% | $60.98M+1.3% | $63.98M-0.2% | $64.97M+0.9% | ||
| $80.01M-10.0% | $81.55M-27.4% | $81.08M-39.8% | $77.09M-55.5% | $88.95M-55.0% | ||
| —— | -$1.36M-45.7% | -$1.26M-39.3% | -$1.15M-32.4% | -$1.04M-24.9% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | $7.65M+182% | -$56.43M-278% | -$42.44M-588% | ||
| —— | —— | —— | —— | —— | ||
| $11.4M— | $12.16M— | $5.25M— | —— | —— | ||
| -$2.2M— | -$2.17M— | -$2.28M— | —— | —— | ||
| -$21.81M+72.4% | -$32.39M+52.8% | -$28.08M+62.2% | -$75.31M-139% | -$78.92M-265% | ||
| $29.82M-0.1% | $30.08M+7.1% | $29.93M+23.2% | $29.89M+19.3% | $29.84M+15.2% | ||
| -$28.14M-78.0% | -$27.93M-84.8% | -$22.29M-38.4% | -$22.65M-66.0% | -$15.81M+14.0% | ||
| -$166.22M+41.0% | -$171.06M+46.5% | -$165.82M+50.5% | -$237.71M+22.1% | -$281.85M+4.2% | ||
| $1.98M-96.9% | $7.67M-87.7% | $21.37M-59.1% | $36.46M-12.3% | $63.45M+126% | ||
| $310.61M+62.5% | $418.63M— | $401.84M— | $320.13M— | $191.18M— | ||
| $134.08M— | $25.9M— | -$3.95M— | $64.96M— | —— | ||
| —— | —— | -$511K-165% | -$609K-391% | -$658K-165% | ||
| —— | —— | -$348.47M-264% | -$285.86M-221% | -$248.81M-239% | ||
| $166K-79.5% | $354K-60.5% | $532K-47.4% | $708K-37.9% | $810K-36.1% | ||
| —— | $0— | $0-100% | $0-100% | $0-100% | ||
| $17.96M+1,732% | $17.78M+1,122% | $9.43M+535% | -$973K+51.8% | -$1.1M+65.3% | ||
| —— | —— | $280K— | $152K— | -$50K— | ||
| —— | —— | -$504.58M-16.5% | -$524.39M-32.3% | -$531.81M-43.2% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| -$28.14M-78.0% | -$27.93M-84.8% | -$22.29M-38.4% | -$22.65M-66.0% | -$15.81M+14.0% | ||
| —— | —— | $7.65M+182% | -$56.43M-278% | -$42.44M-588% | ||
| $11.4M— | $12.16M— | $5.25M— | —— | —— | ||
| —— | —— | —— | -$6.04M— | -$8.35M— | ||
| —— | —— | —— | -$12.9M+34.0% | -$27.14M-310% | ||
| —— | $0+100% | -$279.25K+76.4% | -$558.5K+55.1% | -$837.75K+36.0% | ||
| $29.82M-0.1% | $30.08M+7.1% | $29.93M+23.2% | $29.89M+19.3% | $29.84M+15.2% | ||
| -$2.2M— | -$2.17M— | -$2.28M— | —— | —— | ||
| —— | —— | -$511K-165% | -$609K-391% | -$658K-165% | ||
| —— | $0— | $0-100% | $0-100% | $0-100% | ||
| —— | —— | —— | —— | —— | ||
| $166K-79.5% | $354K-60.5% | $532K-47.4% | $708K-37.9% | $810K-36.1% | ||
| —— | —— | —— | —— | —— | ||
| -$21.81M+72.4% | -$32.39M+52.8% | -$28.08M+62.2% | -$75.31M-139% | -$78.92M-265% | ||
| -$28.14M-78.0% | -$27.93M-84.8% | -$22.29M-38.4% | -$22.65M-66.0% | -$15.81M+14.0% | ||
| -$168.2M+51.3% | -$178.72M+53.2% | -$187.19M+51.7% | -$274.17M+20.9% | -$345.3M-7.2% | ||
| -$168.2M+51.3% | -$178.72M+53.2% | -$187.19M+51.7% | -$274.17M+20.9% | -$345.3M-7.2% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Ginkgo Bioworks generate?
- Ginkgo Bioworks (DNA) generated -$166.2M in operating cash flow over the trailing twelve months.
- What is Ginkgo Bioworks's free cash flow?
- After $2.0M of capital expenditures, Ginkgo Bioworks's free cash flow was -$168.2M over the trailing twelve months, up 51.3% year over year.
- Where does Ginkgo Bioworks's cash flow data come from?
- Every line is extracted from Ginkgo Bioworks's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
